Marc Forth - Aug 31, 2024 Form 4 Insider Report for AEON Biopharma, Inc. (AEON)

Role: CHIEF EXECTUIVE OFFICER, Director
Signature: /s/ Alexander Wilson as attorney-in-fact for Marc Forth
Stock symbol: AEON
Transactions as of: Aug 31, 2024
Transactions value $: $0
Form type: 4
Date filed: 9/4/2024, 09:59 PM
Previous filing: Mar 21, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AEON	Class A Common Stock	Award	$0	+471K	+168.19%	$0.00	751K	Aug 31, 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AEON	Stock Option	Award	$0	+1.26M		$0.00	1.26M	Aug 31, 2024	Class A Common Stock	1.26M	$0.83	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents an award of restricted stock units granted on August 31, 2024 (the "Grant Date"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date.
F2	Includes an award of restricted stock units ("RSUs") in the amount of 279,855 previously granted on April 26, 2023, which were previously reported on July 24, 2023 as derivative securities in Table II due to a clerical error, and which are now being reported as common stock in Table I. The vesting terms for the RSUs have not changed from what was previously reported on July 24, 2023.
F3	Represents an award of stock options granted on August 31, 2024 (the "Grant Date"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date.